27-29-Intas Biopharmaceuticals-Concord Biotec-Veeda
15 June 2010 | News
27
Intas Biopharmaceuticals
Intas Biopharmaceuticals clocked an annual revenue of Rs 115 crore for fiscal 2009–2010. Starting with bio-generics, Intas Biopharmaceuticals has structured its progression to the development of proprietary and innovative recombinant biopharmaceuticals. The Ahmedabad-based company received the European Union – Good Manufacturing Practice (EU-GMP) certification for its manufacturing facility and also received quality certification from Medicines Control Council (MCC) – South Africa and Gulf Cooperation Council (GCC).
Intas has recently launched multiple myeloma drug, Bortezomib injection, in India under the brand name Borviz. The company has signed a Memorandum of Understanding (MoU) with Government of Gujarat for setting up a separate manufacturing facility for Monoclonal Antibodies (MAbs), a recombinant mammalian platform product. The company will invest Rs 160 crores towards setting up a manufacturing facility at Sanand near Ahmedabad.
28
Concord Biotech
Gujarat-based Concord Biotech clocked an annual revenue of Rs 111.07 crore for the fiscal year 2009-2010. It is an R&D based biotechnology company, having focus on the fermentation, semi-synthetic and synthesis based products. Since its inception in 2000, Concord has recorded an excellent growth through diversification and process improvements. Having a state-of-the-art US FDA approved facility, Concord is a globally recognized supplier of fermentation-based API's and enzymes. It also offers strain improvement and contract fermentation services.
The existing portfolio of products includes API's in the immunosuppressant, antibiotic, hypolipemic segments and enzymes. It has the capacity and flexibility to ferment and develop processes for a variety of microbial organisms. Concord is the largest producer of Penicillin-G Amidase enzyme and is exporting it to a number of companies in China, Europe and the US, besides having 90 percent market share in India. It is also producing and exporting Lovastatin and Tacrolimus to Europe and other countries. The company is planning to start the production of simvastatin and pravastatin in its new facility.
29
Veeda Clinical Research
Veeda Clinical Research is a full service global CRO specializing in the early clinical development of drugs. The company's annual revenues for the last fiscal year amounted to Rs 112 crore. With state-of-the-art facilities in the UK, India and Belgium, Veeda provides a full range of services in phase I and IIa clinical research to the pharmaceutical and botechnology industries globally. In last three years, Veeda has been growing at a rate of 70 percent and it aims at growing at a faster pace to achieve a turnover of Rs 325 crore in the next three years. The company, in a span of five years, has made its presence in the US, Europe, India and South East Asia. Till date, it has acquired four CROs in Europe and is on the lookout for an acquisition in the US.
Veeda was awarded supplementary accreditation for conducting clinical pharmacology phase I trials in Europe by the Medicines and Healthcare products Regulatory Agency (MHRA) and was awarded $10.2 million of new clinical research programs in the month of December 2008 from five new clients. It also made the acquisition of US-based International Oncology Network Clinical Research in 2009.
Intas Biopharmaceuticals
| MD | Dr Urmish Chudgar |
 |
| Business | R&D, manufacturing and marketing of recombinant
products and oncology drugs |
|
| Start-up Year | 2006 | |
| Biotech Revenue | Rs 115 crore | |
| Address | Plot No 423/P/A/GIDC, Moraiya, Sarkhej-Bavla
highway, Tal: Sanand, Ahmedabad-382210 |
|
| Tel | + 91-2717-660101 | |
| Fax | +91-2717-251189 | |
| Website | www.intasbiopharma.co.in |
Intas Biopharmaceuticals clocked an annual revenue of Rs 115 crore for fiscal 2009–2010. Starting with bio-generics, Intas Biopharmaceuticals has structured its progression to the development of proprietary and innovative recombinant biopharmaceuticals. The Ahmedabad-based company received the European Union – Good Manufacturing Practice (EU-GMP) certification for its manufacturing facility and also received quality certification from Medicines Control Council (MCC) – South Africa and Gulf Cooperation Council (GCC).
Intas has recently launched multiple myeloma drug, Bortezomib injection, in India under the brand name Borviz. The company has signed a Memorandum of Understanding (MoU) with Government of Gujarat for setting up a separate manufacturing facility for Monoclonal Antibodies (MAbs), a recombinant mammalian platform product. The company will invest Rs 160 crores towards setting up a manufacturing facility at Sanand near Ahmedabad.
28
Concord Biotech
| CEO | Sudhir Vaid |  |
| Business | Manufacturing of bulk drugs |
|
| Start-up Year | 2000 | |
| Biotech Revenue | Rs 111.07 crore | |
| Address | 302, Sakar-III, Opp: Gujarat High Court, Off ITO
Circle, Ashram Road, Ahmedabad-380014 |
|
| Tel | 091-79-27544998, 27543557 | |
| Fax | 091-79-27540802 | |
| Website | www.concordbiotech.com |
Gujarat-based Concord Biotech clocked an annual revenue of Rs 111.07 crore for the fiscal year 2009-2010. It is an R&D based biotechnology company, having focus on the fermentation, semi-synthetic and synthesis based products. Since its inception in 2000, Concord has recorded an excellent growth through diversification and process improvements. Having a state-of-the-art US FDA approved facility, Concord is a globally recognized supplier of fermentation-based API's and enzymes. It also offers strain improvement and contract fermentation services.
The existing portfolio of products includes API's in the immunosuppressant, antibiotic, hypolipemic segments and enzymes. It has the capacity and flexibility to ferment and develop processes for a variety of microbial organisms. Concord is the largest producer of Penicillin-G Amidase enzyme and is exporting it to a number of companies in China, Europe and the US, besides having 90 percent market share in India. It is also producing and exporting Lovastatin and Tacrolimus to Europe and other countries. The company is planning to start the production of simvastatin and pravastatin in its new facility.
29
Veeda Clinical Research
| Founders | Apurva Shah and Binoy Gardi |  |
| Business | Early clinical development services |
|
| Start-up Year | 2005 | |
| Biotech Revenue | Rs 110 crore | |
| Address | Veeda Clinical Research – India, Shivalik Plaza-A,
Near IIM, Ambawadi, Ahmedabad- 380 015 |
|
| Tel | +91 79 3001 3000 | |
| Fax | +91 79 3001 3010 | |
| Website | www.veedacr.com |
Veeda Clinical Research is a full service global CRO specializing in the early clinical development of drugs. The company's annual revenues for the last fiscal year amounted to Rs 112 crore. With state-of-the-art facilities in the UK, India and Belgium, Veeda provides a full range of services in phase I and IIa clinical research to the pharmaceutical and botechnology industries globally. In last three years, Veeda has been growing at a rate of 70 percent and it aims at growing at a faster pace to achieve a turnover of Rs 325 crore in the next three years. The company, in a span of five years, has made its presence in the US, Europe, India and South East Asia. Till date, it has acquired four CROs in Europe and is on the lookout for an acquisition in the US.
Veeda was awarded supplementary accreditation for conducting clinical pharmacology phase I trials in Europe by the Medicines and Healthcare products Regulatory Agency (MHRA) and was awarded $10.2 million of new clinical research programs in the month of December 2008 from five new clients. It also made the acquisition of US-based International Oncology Network Clinical Research in 2009.
